TGFB1 and prostatitis: KLK1 administration inhibited TGF-β-related fibrosis signaling pathways, increased the expression of eNOS as well as ameliorated hypoxia and oxidative stress, and suppressed the proangiogenic VEGF in prostatitis rats.